Evidence map›Paper›PMID 41195279›Full record

ArticleFrontiers in oncology2025

A compact, lightweight, variable-energy cyclotron for conventional and FLASH ion beam radiotherapy.

D Winklehner, J V Minervini, L Bromberg, E Forton, J Mandrillon, P C Michael, A Radovinsky

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

D WinklehnerDepartment of Physics, Massachusetts Institute of Technology, Cambridge, MA, United States.
J V MinerviniPlasma Science and Fusion Center, Massachusetts Institute of Technology, Cambridge, MA, United States.
L BrombergPlasma Science and Fusion Center, Massachusetts Institute of Technology, Cambridge, MA, United States.
E FortonIon Beam Applications SA, Louvain-la-Neuve, Belgium.
J MandrillonIon Beam Applications SA, Louvain-la-Neuve, Belgium.
P C MichaelPlasma Science and Fusion Center, Massachusetts Institute of Technology, Cambridge, MA, United States.
A RadovinskyPlasma Science and Fusion Center, Massachusetts Institute of Technology, Cambridge, MA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The advantage of ion beam radiotherapy for cancer lies in its low dose proximal and distal to the tumor, owed to an energy-dependent depth-dose profile, the Bragg-peak. However, conventional techniques to achieve different energies often rely on degraders, which compromise the quality and intensity of the beam and produce secondary radiation. Methods: We propose a novel conceptual design for a compact accelerator capable of delivering ion beams (e.g., protons or carbon ions) with variable energy from 70 to 230 MeV/amu. Removing all magnetic iron from the device yields a linear relationship between coil current and cyclotron magnetic field, and, thus, smooth scaling of the output beam energy. We base our findings on finite elements calculations, particle ray-tracing and particle-in-cell simulations. Results: In the absence of magnetic iron, we achieve a much lighter system with improved magnetic shielding and significantly reduced secondary radiation that can provide ion beams at variable energy while providing the high beam intensity necessary for the promising FLASH technique at all output energies. Discussion: This design represents a promising advancement in ion beam radiotherapy, combining energy flexibility, reduced radiation hazards, and compatibility with high-intensity techniques. It may pave the way for more efficient, compact, and clinically versatile accelerator systems.

Indexed as

cyclotronFLASH radiotherapyparticle acceleratorsradiotherapysuperconductivity

Identifiers

PMID41195279
PMCPMC12583090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.